journal article·2023-09Open access

Crystal structure of danofloxacin mesylate (C 19 H 21 FN 3 O 3 )(CH 3 O 3 S)

Tawnee M. Ens, James A. Kaduk, Anja Dosen, Thomas N. Blanton

Powder Diffraction· Volume 38· Issue 3

Abstract

The crystal structure of danofloxacin mesylate has been solved and refined using synchrotron X-ray powder diffraction data and optimized using density functional theory techniques. Danofloxacin mesylate crystallizes in space group P1 (#1) with a = 6.77474(8), b = 12.4973(4), c = 12.82826(28) Å, α = 84.8709(29), β = 87.7501(10), γ = 74.9916(4)°, V = 1044.723(11) Å 3 , and Z = 2. The protonation of the danofloxacin cations was established by the analysis of potential intermolecular interactions and differs from that expected from isolated-cation calculations. The crystal structure consists of alternating layers of cations and anions parallel to the ac -plane. There is parallel stacking of the oxoquinoline rings along the a -axis. The expected N–H⋯O hydrogen bonds between the cations and anions are not present. Each cation makes an N–H⋯O hydrogen bond with the other cation, resulting in zig-zag chains along the a -axis. Both cations have strong intramolecular O–H⋯O hydrogen bonds. There are several C–H⋯O hydrogen bonds between the danofloxacin cations and mesylate anions. The powder pattern has been submitted to ICDD® for inclusion in the Powder Diffraction File™ (PDF®).
Source: crossref · Quality: baseline

Research context

OpenAlex topics: X-ray Diffraction in Crystallography · Crystallography and molecular interactions · Polymer Synthesis and Characterization

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (39)

Show source-provided references
1. 10.3749/canmin.46.5.150110.3749/canmin.46.5.1501 ↗
2. 10.1107/S205252061800233010.1107/S2052520618002330 ↗
3. 10.1107/S010876819901508610.1107/S0108768199015086 ↗
4. 10.3406/bulmi.1907.282010.3406/bulmi.1907.2820 ↗
5. 10.1038/s41598-021-90647-z10.1038/s41598-021-90647-z ↗
6. 10.1107/S002188981101462210.1107/S0021889811014622 ↗
7. 10.1107/S002188981301311310.1107/S0021889813013113 ↗
8. 2016
9. 10.1002/anie.19951555110.1002/anie.199515551 ↗
10. 10.1107/S090904950801843810.1107/S0909049508018438 ↗
11. 10.1007/BF0054909610.1007/BF00549096 ↗
12. Bravais · 1866
13. 10.1107/S002188981300353110.1107/S0021889813003531 ↗
14. 10.1107/S160057672100291010.1107/S1600576721002910 ↗
15. 10.1063/1.46788210.1063/1.467882 ↗
16. 10.1017/S088571561400051710.1017/S0885715614000517 ↗
17. 10.1093/nar/gkac95610.1093/nar/gkac956 ↗
18. Center for Veterinary Medicine, Food and Drug Administration, U.S. Department of Health and Human Services. 2022. “Extralabel Use and Antimicrobials”. https://www.fda.gov/animal-veterinary/antimicrobial-resistance/extralabel-use-and-antimicrobials.
19. 10.1107/S002188980604211710.1107/S0021889806042117 ↗
20. CRYSTAL23: A Program for Computational Solid State Physics and Chemistry10.1021/acs.jctc.2c00958 ↗
21. 10.1038/sj.bjp.070697410.1038/sj.bjp.0706974 ↗
22. The European Agency for the Evaluation of Medicinal Products, Veterinary Medicines Evaluation Unit, Committee for Veterinary Medicinal Products. 1997. “Danofloxacin Summary Report (2).” https://www.ema.europa.eu/en/documents/mrl-report/danofloxacin-summary-report-2-committee-veterinary-medicinal-products_en.pdf.
23. 10.1107/S205252061600395410.1107/S2052520616003954 ↗
24. 10.1017/S088571561900081210.1017/S0885715619000812 ↗
25. A New Law of Crystal Morphology Extending the Law of Bravais
26. 10.1002/jcc.2315310.1002/jcc.23153 ↗
27. Center for Veterinary Medicine, Food and Drug Administration, U.S. Department of Health and Human Services. 2023. “Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to their Microbiological Effects on Bacteria of Human Health Concern; Guidance for Industry; Draft Guidance”. https://www.fda.gov/media/69949/download.
28. 10.1016/0927-0256(96)00008-010.1016/0927-0256(96)00008-0 ↗
29. Investigations into the Performance of Travelling Wave Enabled Conventional and Cyclic Ion Mobility Systems to Characterise Protomers of Fluoroquinone Antibiotic Residues
30. 10.1107/S002188989800600110.1107/S0021889898006001 ↗
31. 10.1107/S205252061402290210.1107/S2052520614022902 ↗
32. 10.1063/1.296926010.1063/1.2969260 ↗
33. Wavefunction, Inc. 2020. Spartan ‘18. Version 1.4.5. Wavefunction Inc., 18401 Von Karman Ave., Suite 370, Irvine CA 96212.
34. 10.1021/ci049780b10.1021/ci049780b ↗
35. 10.1017/S088571561800082910.1017/S0885715618000829 ↗
36. Crystal Impact. 2022. Diamond. V. 4.6.8. Crystal Impact – Dr. H. Putz & Dr. K. Brandenburg. Windows.
37. 10.1021/ar00172a00510.1021/ar00172a005 ↗
38. 2021
39. 10.1107/S160057671901409210.1107/S1600576719014092 ↗